PolQi2
Based on 3 publication(s) in Google Scholar
PolQi2 is a PolΘ inhibitor that targets and inhibits alt-EJ (alternative end-joining) repair by inhibiting the helicase domain at the N-terminus of PolΘ. PolQi2 enhances the precision and integration efficiency of gene editing at different loci and in various cell lines. Furthermore, the combined use of PolQi2 with DNA-PK inhibitors reduces the off-target effects of Cas9. PolQi2 can be used in gene editing research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.91%
- CAS No.: 2565638-16-4
- Formule: C21H16ClN5O3S
- Masse moléculaire:453.90
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Aging Compound Library
HY-L034
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
Publications Citing Use of MedChemExpress (MCE) PolQi2
More
Customer Validation & Images
-
Others
-
Others
-
Others
-
Flow Cytometry
-
Flow Cytometry
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
|
Helicase |
PolQi2 (3 μM, 14 days), in combination with DNA-PK inhibitors (1 μM, 14 days), efficiently and stably achieves targeted gene insertion in HeLa and Jurkat cells, without adversely affecting cell proliferation [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2565638-16-4
-
Appearance Solid
-
Masse moléculaire 453.90
-
Formule C21H16ClN5O3S
-
Color White to off-white
-
SMILES
O=C(C1=CC=NC=C1C2=C(OC)C=CC=C2)NC3=NN=C(S3)OCC4=NC=C(C=C4)Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Biotechnol
Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations. [Abstract]2024 Nov 27. PMID: 39604565
PolQi2 purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2024 Nov 27. [Abstract]
Quantification by long-read sequencing of the fraction of total reads with a length greater than a defined size and the quantified frequency of deletions larger than 1 kb in edited RPE-1 p53−/− cells was performed. Editing with combined AZD7648 and PolQi2 (3 µM; 3 d) reduced AZD7648-induced kilobase-scale deletions.
PolQi2 purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2024 Nov 27. [Abstract]
Editing with combined AZD7648 and PolQi2 (3 μM; 3 d) maintained elevated HDR levels. Frequencies of HDR and indels detected by short-read sequencing in RPE-1 p53−/− and RPE-1 p53+/+ cells edited at HBB, CCR5, and GAPDH were recorded.
-
PolQi2 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Nov 29.
PolQi2, a potent Polθ inhibitor, suppresses the MMEJ repair pathway and enhances HDR efficiency during CRISPR/Cas9-mediated gene editing. Splenic T cells from transgenic Cas9 mice were activated with Dynabeads and transduced with the specified MOI of AAV after 48 hours in 1 μM AZD7468 and 3 μM PolQi2. Percentage of cells expressing GFP above baseline level was determined by flow cytometry 5 days after transduction.
PolQi2 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Nov 29.
Knock-in efficiency was assessed by flow cytometry as the percentage of GFP+ cells among CD3- cells. Treatment with AZD7648 and PolQi2 (3 μM) resulted in the highest editing efficiency, achieving a knock-in rate of up to 80% under AAV transduction conditions.
-
bioRxiv
2025 May 13:2025.05.10.653283. PMID: 40462907
PolQi2 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 May 13:2025.05.10.653283. [Abstract]
Quantification of Ec78 retron precise editing was performed in comparison with no reverse transcriptase control (No RT), in the absence (Ec78) or the presence (Ec78 + inhib) of inhibitors, AZD7648 and PolQi2 (3 μM; 48 h), and the same experiments were conducted with the Mestre-1531 retron (RT 1531) using the same inhibitors.
Solvant et solubilité
DMSO : 70 mg/mL (154.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.51 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2031 mL | 11.0156 mL | 22.0313 mL | 55.0782 mL |
| 5 mM | 0.4406 mL | 2.2031 mL | 4.4063 mL | 11.0156 mL | |
| 10 mM | 0.2203 mL | 1.1016 mL | 2.2031 mL | 5.5078 mL | |
| 15 mM | 0.1469 mL | 0.7344 mL | 1.4688 mL | 3.6719 mL | |
| 20 mM | 0.1102 mL | 0.5508 mL | 1.1016 mL | 2.7539 mL | |
| 25 mM | 0.0881 mL | 0.4406 mL | 0.8813 mL | 2.2031 mL | |
| 30 mM | 0.0734 mL | 0.3672 mL | 0.7344 mL | 1.8359 mL | |
| 40 mM | 0.0551 mL | 0.2754 mL | 0.5508 mL | 1.3770 mL | |
| 50 mM | 0.0441 mL | 0.2203 mL | 0.4406 mL | 1.1016 mL | |
| 60 mM | 0.0367 mL | 0.1836 mL | 0.3672 mL | 0.9180 mL | |
| 80 mM | 0.0275 mL | 0.1377 mL | 0.2754 mL | 0.6885 mL | |
| 100 mM | 0.0220 mL | 0.1102 mL | 0.2203 mL | 0.5508 mL |
PolQi2 Related Classifications
HY-150279 Related Classifications
Powered by Bioz